Amphetamine Completed Phase 2 Trials for Attention Deficit Disorder With Hyperactivity Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00151996Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00557011NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD